← Back to Screener
Arcellx, Inc. Common Stock (ACLX)
Price$115.00
Favorite Metrics
Price vs S&P 500 (26W)23.80%
Price vs S&P 500 (4W)-9.25%
Market Capitalization$6.73B
All Metrics
Book Value / Share (Quarterly)$6.95
P/TBV (Annual)12.66x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-3.67
Price vs S&P 500 (YTD)72.32%
Net Profit Margin (TTM)-1027.25%
EPS (TTM)$-4.06
10-Day Avg Trading Volume0.60M
EPS Excl Extra (TTM)$-4.06
EPS (Annual)$-4.07
ROI (Annual)-56.90%
Cash / Share (Quarterly)$7.77
Revenue Growth QoQ (YoY)-89.17%
ROA (Last FY)-37.90%
Revenue Growth TTM (YoY)-79.35%
EBITD / Share (TTM)$-4.36
ROE (5Y Avg)-49.03%
Operating Margin (TTM)-1135.61%
Cash Flow / Share (Annual)$-3.67
P/B Ratio16.72x
P/B Ratio (Quarterly)9.37x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)298.30x
ROA (TTM)-36.24%
EPS Incl Extra (Annual)$-4.07
Current Ratio (Annual)4.44x
Quick Ratio (Quarterly)4.36x
3-Month Avg Trading Volume1.84M
52-Week Price Return89.57%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$5.47
P/S Ratio (Annual)301.90x
Asset Turnover (Annual)0.04x
52-Week High$115.13
EPS Excl Extra (Annual)$-4.07
CapEx CAGR (5Y)21.19%
26-Week Price Return32.55%
Quick Ratio (Annual)4.36x
13-Week Price Return64.69%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.44x
Enterprise Value$6,647.841
Asset Turnover (TTM)0.04x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1026.95%
Cash / Share (Annual)$7.77
3-Month Return Std Dev154.48%
Net Income / Employee (TTM)$-1
ROE (Last FY)-56.90%
EPS Basic Excl Extra (Annual)$-4.07
P/FCF (TTM)24.85x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-4.06
ROI (TTM)-55.42%
P/S Ratio (TTM)301.90x
Revenue / Share (Annual)$0.40
Tangible BV / Share (Annual)$4.65
Price vs S&P 500 (52W)54.48%
Year-to-Date Return76.46%
5-Day Price Return0.16%
EPS Normalized (Annual)$-4.07
ROA (5Y Avg)-34.43%
Net Profit Margin (Annual)-1027.25%
Month-to-Date Return0.20%
Cash Flow / Share (TTM)$-2.73
EBITD / Share (Annual)$-4.38
Operating Margin (Annual)-1135.61%
LT Debt / Equity (Annual)10.18x
ROI (5Y Avg)-44.98%
LT Debt / Equity (Quarterly)2.16x
EPS Basic Excl Extra (TTM)$-4.06
P/TBV (Quarterly)9.75x
P/B Ratio (Annual)9.37x
Pretax Margin (TTM)-1026.95%
Book Value / Share (Annual)$6.95
Price vs S&P 500 (13W)61.82%
Beta0.19x
P/FCF (Annual)36.14x
Revenue / Share (TTM)$0.39
ROE (TTM)-55.42%
52-Week Low$47.86
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.23
4.23
3.42
2.78
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ACLXArcellx, Inc. Common Stock | 301.90x | -79.35% | — | — | $115.00 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Arcellx is a clinical-stage biotechnology company developing cell-based immunotherapies for cancer and other difficult-to-treat diseases. The company's pipeline targets blood cancers including multiple myeloma and acute myeloid leukemia, along with solid tumors and select non-oncology indications.